Soluble ST2 (sST2) is a promising biomarker in inflammation, atherosclerosis, and cardiovascular diseases. We investigated the association between serum sST2 and poor outcome in patients with transient ischaemic attack (TIA)/ischaemic stroke.
Patients within 24 h after onset and with measured serum sST2 were prospectively enrolled in this study. Poor outcome was a combination of a new stroke event (ischaemic or haemorrhagic) and all-cause death within 90 days and 1 year. The associations of serum sST2 with poor outcome were analysed by Cox proportional hazards.
Among 430 patients included, the median (interquartile range) of sST2 was 17.72 (9.31-28.84) ng/mL. 19 (4.4%) and 38 (8.8%) patients experienced poor outcome within 90 days and 1 year, respectively. Compared with the lowest sST2 tertile, hazard ratios (95% confidence intervals) for the highest tertile were 5.14 (1.43-18.51) for poor outcome within 90 days and 3.00 (1.29-6.97) at 1 year after multivariate adjustments. Adding sST2 to a prediction model significantly improved risk stratification of poor outcome in TIA/ischaemic stroke, as observed by the continuous net reclassification improvement (NRI) of 60.98% (95% CI: 15.37%-106.6%, P=0.009) and integrated discrimination improvement (IDI) of 2.63% (95% CI: 0.08%-5.18%, P=0.043) at 90 days, and the continuous NRI of 41.68% (95% CI: 8.74%-74.61%, P=0.013) at 1 year.
Increased serum sST2 levels in TIA/ischaemic stroke were associated with increased risks of poor outcome within 90 days and 1 year, suggesting that serum sST2 may be a potential long-term prognostic biomarker for TIA/ischaemic stroke.
This article is protected by copyright. All rights reserved.
About The Expert
Xuan Tian
Yinan Guo
Xiao Wang
Lulu Pei
Xin Wang
Jun Wu
Shilei Sun
Yusheng Li
Mingming Ning
Ferdinando S Buonanno
Yuming Xu
Bo Song
References
PubMed